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Abstract 
 
Introduction: Sexually transmitted infections (STIs) are a major public health issue in 
Australia, particularly among men-who-have-sex-with-men (MSM). Timely STI prevalence 
data for the MSM population is essential to support the implementation of public health 
interventions. This study aimed to calculate the prevalence of three bacterial sexually 
transmitted pathogens, namely Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and 
Mycoplasma genitalium (MG), in asymptomatic HIV-negative MSM attending Western 
Sydney Sexual Health Centre (WSSHC). The associations between patient-related factors 
(demographic, behavioural and clinical factors) and the presence/absence of bacterial STI 
pathogens were investigated. 
Methods: This study will calculate the prevalence and risk factors using a retrospective cross-
sectional approach relying on pre-collected patient data and laboratory testing results. A 
multivariable logistic regression model using SPSS v23 was used to analyse the correlations of 
STIs diagnosis and specific demographic, behavioural, and clinical risk factors. Participants 
were asymptomatic MSM aged 18 years old and over attending the Express Clinic service or 
computer-assisted self-interview (CASI) in WSSHC and undergoing onsite STIs screening 
between 1 February and 31 May 2017. The researcher reviewed both the print out of the CASI 
data and laboratory testing result sheets attached to patient notes and electronic database. 
Ethical clearance was obtained from the Western Sydney Local Health District’s 
(WSLHD)Human Research Ethics Committee (HREC) along with WSLHD Research 
Governance Office (RGO) approval. 
Results: A total of 307 asymptomatic MSM were involved in this study. Of 307 MSM, 82 
(26.7%) were found to have at least one pathogen at one anatomical site. The three most 
prevalent diagnoses identified among asymptomatic MSM were ano-rectal CT with a 
prevalence of 9.8% (95% CI: 6.5 to 13.0), ano-rectal MG with 9.4% (95% CI: 6.2 to 12.7), and 
oro-pharyngeal NG with 5.5% (95% CI: 2.9 to 8.1). Meanwhile, the prevalence of 
asymptomatic STI cases was relatively low in oro-pharyngeal CT, 1.0% (95% CI: 0.04 to 2.3) 
and urethral NG, 0.3% (95% CI: 0.04 to 2.3). MG was not detected in oro-pharyngeal samples. 
Co-infections occurred in 15/307 MSM (4.9%), most frequently at ano-rectal sites. A 
multivariate model demonstrated that MSM who practised more condomless sex (adjusted odds 
ratio/AOR=2.39, 95% CI: 1.05 to 5.51, p=0.04) and had past STI episodes (AOR=1.92, 95% 
CI: 1.01 to 3.62, p=0.04) were more likely to have STI diagnosis. Although significant in a 
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univariate analysis, use of HIV pre-exposure prophylaxis (PrEP) was not found to be associated 
with STI diagnosis in the multivariate model.  
Conclusion: Bacterial STIs were common among asymptomatic HIV-negative MSM attending 
the Express Clinic in WSSHC, Parramatta. Infections affecting ano-rectal sites remained 
concerning within this population, as high-risk sexual behaviours were still frequently reported. 
This study found a high prevalence of MG infection which was previously not considered as a 
major infection. This study has provided an overview of the current prevalence of STIs among 
asymptomatic MSM attending WSSHC. These results highlight the importance of STI 
screening strategies for MSM. Given that attendance at a Sexual Health clinic may lead to 
selection bias, further works are needed to assess the burden of bacterial STIs among 
asymptomatic community-based MSM.  
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Chapter I  
Introduction 
 
This thesis study aims to calculate the prevalence of asymptomatic bacterial sexually 
transmitted infections (STIs) among asymptomatic HIV-uninfected men who have sex with 
men (MSM) attending sexual health service in Western Sydney Sexual Health Center 
(WSSHC), Parramatta, New South Wales (NSW), Australia. MSM in Australia remain an 
important population on their role in spreading HIV/STIs. The prevalence of three bacterial 
STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) was 
calculated, and anatomical sites of infection (urethra, ano-rectum, and oro-pharynx) were 
specified. This chapter will discuss the background of the study, including essential terms used, 
aims and significance of the study, and the organisational layout of thesis. 
1.1 Background of the study 
1.1.1 Epidemiology of bacterial STIs in Australia 
Across the globe, STIs remain one of the most important groups of infectious diseases with an 
estimated one million new transmissions every day (1). These infections can be transferred 
from one person to another through sexual contact. In this context, sexual contact is not limited 
to traditional views of what sexual intercourse might entail (vaginal and/or anal intercourse) 
but might also involve mouth (oral sex and kissing) and the shared use of sex toys (2). There 
are more than 30 pathogens, ranged from viruses, bacteria, fungus, protozoa, and parasite that 
can cause STIs. The four main bacterial STI pathogens are Chlamydia trachomatis (CT), 
Neisseria gonorrhoeae (NG), Treponema pallidum (syphilis) and Mycoplasma genitalium 
(MG). Haemophilus ducreyi and Klebsiella granulomatis (formerly Calymmatobacterium 
granulomatis) are other bacterial causes of genital ulceration with a lower prevalence, though 
are still endemic in particular areas. Bacterial STIs are curable diseases but, in the absence of 
vaccines, the high rate of asymptomatic cases leads to difficult control of the diseases. 
Based on the Annual Surveillance Report on HIV / AIDS, Viral Hepatitis & Sexually 
Transmissible Infections, chlamydia was the most commonly reported STI in Australia which 
caused 71,751 cases in 2016, followed by gonorrhoea with 23,887 cases and syphilis with 3,367 
cases (3). Of the three pathogens, notifications for gonorrhoea and syphilis had risen nearly 
twice as much in comparison with notification for 2015 (4). Australia lacks national 
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surveillance data for MG infection as testing is sporadic and generally recommended only in 
the management of specified clinical scenarios; in addition, as it is a non-notifiable disease, 
laboratories do not report on positive MG results. Most STIs are diagnosed in at-risk 
populations, from now on referred to as key populations, such as young people, sex workers, 
MSM, injecting drug user (IDU), transgender, prisoners, and Aboriginal and Torres Strait 
Islander people (5). In Australia, MSM living in urban areas and Aboriginal heterosexuals, 
particularly those residing in remote rural areas,  are two populations with a high prevalence of 
STIs (5). Among MSM, infections at the extra-genital sites (oro-pharynx and ano-rectum) are 
far more common than at the urethral site (3). Unfortunately, infections at both these sites are 
often asymptomatic and thus only detectable through opportunistic, or preferably, regular 
screening of MSM. 
1.1.2 Asymptomatic MSM and the importance of screening.  
According to the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance 
(ACCESS) report for New South Wales (NSW) in 2017, the prevalence of STI in MSM was 
highest compared with other populations, with 8% gonorrhoea, 8% chlamydia and 1.7% 
syphilis (6). Data on the prevalence of MG infection is limited. Based on the site of infection, 
oro-pharyngeal and ano-rectal infections are found mostly among MSM. However, infected 
individuals are often asymptomatic. Asymptomatic infections refer to situations in which a 
patient has no symptoms of the illness even though the disease is positively confirmed by 
laboratory diagnosis. Although the individual may be symptom-free, affected organs may 
continue to be damaged, and the potential to transmit infections to others is still possible. For 
MSM, unprotected anal intercourse, oral sex, and even kissing may results in substantial 
tranmissions/acquisitions of gonorrhoea, chlamydia, and MG infections from/to the ano-rectal 
and oro-pharyngeal sites which can account for the high prevalence of asymptomatic STIs 
among MSM (7).  
The relatively high prevalence of asymptomatic STI cases results in a signficant challenge for 
STI control programs, so intensive STI screening programs must be a mainstay of the public 
health approach to controlling bacterial STIs in key populations.  Within New South Wales 
(NSW), the Sexually Transmissible Infections in Gay Men Action Group (STIGMA) guideline 
recommends that MSM undertake STI screening at least once a year, and up to four times a 
year if at high-risk based on the following categories: unprotected anal sex, more than 10 
partners in the last six months, group sex, using recreational drugs during sex, and HIV-positive 
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(8). To improve access to STI testing, the NSW government provide sexual health clinics in 
major urban areas which are free of charge and accessible to many key populations.  
1.1.3 Western Sydney Sexual Health Centre (WSSHC) and Express clinic 
The Western Sydney Sexual Health Centre (WSSHC) is a sexual health service based in 
Parramatta and is the only publicly-funded sexual health service in Western Sydney Local 
Health District (WSLHD). WSLHD comprises five local government areas (Auburn, 
Blacktown, The Hills Shire, Holroyd and Parramatta) (9). This facility provides HIV/STI 
testing and treatment, HIV pre- and post-exposure prophylaxis (PrEP/PEP) as well as 
psychological and social work support for patients. Traditionally, the attendance process begins 
with patient triage which is conducted by a nurse. For symptomatic patients or patients 
requiring PrEP/PEP, clinicians will take sexual histories, undertake medical examinations and 
collect specimens (urine, swabs and blood) (9). Clinical specimens are sent to the pathology 
laboratory at Westmead Hospital using a once to thrice daily courier transport system. 
The Express Clinic was introduced in 2013 for the management of asymptomatic patients 
requiring STI screening in order to improve clinic flow and patient satisfaction. The Express 
service relies on patients self-entering their sexual history data into a computer through 
completion of an on-screen questionnaire which asks specific questions. Clients complete self-
collected sexual history, as well as taking self-collected specimens such as urine, vaginal and 
rectal swabs. If required, nurses collect a blood sample and throat swabs based on risk 
assessments. The Express Clinic is set up for asymptomatic patients, which do not require 
deeper health assessments. The introduction of the Express Clinic has saved waiting time for 
asymptomatic clients, improved clinic operating efficiency and increased cost-effectiveness of 
the service (10, 11). Although there is only limited face-to-face consultation time, the Express 
Clinic has been useful as a means of diagnosing asymptomatic STI cases (11).  
1.2. Aims and Significance of the Study 
The thesis study has the following objectives: 
• To calculate the prevalence of three bacterial urethritis-associated STIs (NG, CT and 
MG) among asymptomatic MSM by the site of infection (urethra, ano-rectum, and oro-
pharynx)  
• To calculate the prevalence of bacterial STIs co-infections among these asymptomatic 
MSM  
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• To identify correlations between either demographic, behavioural, or clinical factors 
and the prevalence of bacterial STIs within asymptomatic MSM 
This study will look at the prevalence of urethritis-associated pathogens among asymptomatic 
MSM at one clinical site (WSSHC, Parramatta). The STI diagnoses identified from different 
sites of infection (urethra, ano-rectum, and oro-pharynx) will show the relative importance of 
each STI by site of infection. Secondly, this study will also investigate certain risk factors 
which have correlations with the STI diagnosis. The final results may provide a useful 
understanding for the STI prevention program for MSM in the future.  
It should be noted that syphilis, the most serious bacterial STI in terms of morbidity and 
mortality, was not studied in this project for four main resons. Firstly, syphilis is frequently 
symptomatic and symptomatic cases would not go through the Express Clinic service. 
Secondly, syphilis is notoriously difficult to stage in asymptomatic people on the basis of a 
single serology result (particularly in the context of a retrospective study). Thirdly, confusion 
frequently exists between whether or not positive serology indicates a new diagnosis or simply 
a prevously treated infection. Finally, syphilis is substantially less prevalent compared to the 
three urethritis-associated bacterial STI pathogens which are the focus of the current study,  
The limited data collected by self-completion of the computer questionnaire will provide 
information on demographic, behavioural, or clinical profiles of the patients and enable an 
analysis of associations between these data and STI diagnoses.  The description of risk factors 
associated with STI diagnosis will be a beneficial input in determining health promotion 
policies, and informing future STI screening efforts for MSM. For the researcher, this study 
will enable the researcher to familiarise himself with research concepts, data collection, data 
analysis and, importantly, enable a critical review of the results and the limitations of the study. 
Furthermore, the study may generate further research questions and might encourage larger 
studies in the future. 
1.3 Organisations of the study 
This thesis contains five chapters: Introduction, Literature Review, Methods, Results, and 
Discussion. Chapter 1 presents the study background, aims and 
the significance of the study. Chapter 2 provides literature reviewed to support the study, 
including the profiles of three pathogens that were studied (CT, NG, MG), epidemiology of 
bacterial STIs, screening for MSM, factors related to STI diagnosis among MSM, and public 
health strategies for the STI prevention. Details of methods used in this study are presented in 
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Chapter 3. Results are illustrated in tables and graphs in Chapter 4, and will be discussed further 
in Chapter 5. Conclusion and recommendation are the final part of Chapter 5.   
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Chapter 2  
Literature Review 
 
This chapter aims to explore related theories and literature that support the principle of this 
study. The discussion will contain the profiles of sexually-transmitted bacteria, epidemiology 
of bacterial STIs, screening for asymptomatic MSM, factors related to STI diagnosis among 
MSM, and public health strategies for the bacterial STI prevention 
2.1 Important Bacterial STIs among MSM 
The three major bacterial STIs associated with urethral discharge as well as ano-rectal and oro-
pharyngeal infections in MSM are gonorrhoea (Neisseria gonorrhoeae), chlamydia 
(Chlamydial trachomatis), and Mycoplasma genitalium infection. Syphilis is another key 
bacterial STI among MSM and is caused by Treponema pallidum. As the focus of this MPhil 
thesis is on bacterial STIs associated with urethritis pathogens, T. pallidum will not be 
discussed further in this section of the literature review. 
2.1.1 Neisseria gonorrhoeae 
Neisseria gonorrhoeae (NG) is a human pathogenic species of the genus Neisseria, a member 
of Neisseriaceae family which is a group of aerobic bacteria (12). This pathogen infects human 
mucosal cells through sexual contact between individuals. As NG is an exclusive human 
pathogen, there are no animal reservoirs. Under the microscope, NG is identified as a Gram-
negative diplococcus (0.6 to 1.0 µm) and characteristically found in a pair (diplococci); the 
individual cocci are coffee-bean shaped appearance (12).  
Neisseria gonorrhoeae is a fastidious organism and grows in specific environmental 
conditions. It requires an aerobic habitat to thrive adequately, but is still able to adapt to 
anaerobic conditions (12). This bacterium grows best at a temperature of 35°C to 36°C on a 
selective medium in an atmosphere of 3-7% of carbon dioxide (12). Neisseria gonorrhoeae is 
both oxidase-positive and catalase-positive when tested biochemically. The cytochrome c 
oxidase, an enzyme present in this bacterium, promotes the bacterial oxidase process. 
Uniquely, N.gonorrhoeae will only oxidise glucose during the sugar utilisation tests which 
distinguishes them from other Neisseria species (13).  
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Gonococcus is also able to catalyse the conversion of hydrogen peroxide to oxygen. In clinical 
settings, the catalase positive profile of the gonococcus is often used to identify N.gonorrhoeae 
using catalase test (3% hydrogen peroxide) and superoxol test (30% hydrogen peroxide) (13). 
Those natural characteristics can help in excluding other Gram-negative bacteria. 
On culture media, NG tends to form small colonies compared with other Neisseria as it requires 
more complex nutrients (12). Colonies of gonococci growing within plate media can be divided 
into four types, the piliated colony (T1 and T2), and non-piliated colony (T3 and T4) (14). 
Piliated colonies, seen during direct isolation of the patients' specimen on selective culture 
media, will form a relatively small colony, while in sub-cultures performed on a non-selective 
culture, non-piliated colonies will develop a large shape of bacterial colony (14). The obvious 
differences exist in the T4 non-piliated colony which is flat, transparent and 1mm larger in 
diameter than T1 and T3 which form small, elevated and granular colonies (14). 
 
PMN: Polymorphonuclear; LPS: Lipopolysaccharides; TNF: Tumor Necrosis Factor 
Source: Morse, in Baron, Chapter 14, Neisseria, Branhamella, Moraxella and Eikenella 
Figure 2.1 Pathogenesis of uncomplicated gonorrhoea 
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Once invading the mucous membrane, gonococcus has several mechanisms to defend against 
host immune response, such as through Reduction modifiable protein (Rmp) and 
Immunoglobulin A (IgA) protease. Rmp is one of three important proteins in the outer 
membrane of gonococcus, along with porins (PorA and PorB), and the opacity proteins (Opa). 
It makes a complex with PorB and LOS in the outer membrane but is not involved in antigenic 
variation . In fact, the immune response to Rmp is significant as the Rmp-mediated 
Immunoglobulin M (IgM) and G (IgG) produced by the host actually block complement-
mediated killing against bacteria Por and LOS . This immune blocking mechanism has is 
a major limitation for vaccine development (20). Moreover, a study in women showed 
individuals with Rmp antibodies are more susceptible to repeat infection of gonorrhoea (20).
The other adaptive mechanism of gonococcus involves the production of IgA protease. In 
human mucous membrane, bacteria will release extracellular IgA protease to inactivate the 
mucosal antibody IgA1. This protease is a potent substance which cleaves both secretory and 
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serum IgA, allows the bacteria to initiate cell attachments (21). This process is said to be the 
most important step of initial gonococcal colonisation in human (21).     
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Figure 2.2. The purulent meatal discharge of male gonococcal urethritis 
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methylene blue/gentian violet stain might provide similar sensitivity and 
specificity
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Mueller-Hinton agar with 5% chocolate sheep blood)
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though this is a less sensitive test (13).
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Spectinomycin was an emerging alternative drug to PPNG in the 1970s (67). This antibiotic 
inhibits bacterial protein translation by binding to the 30S bacterial ribosome. However, a 
mutation in the gonococcal 16sRNA which was an antibiotic interaction pathway caused the 
less bacteriostatic effect of spectinomycin (67). Also, deletions of Val25 and a K26E alteration 
in the 30S ribosomal S5 protein, encoded by the rpsE gene, further blocked the inclusion of 
antibiotic molecules (73). This led to the withdrawal of spectinomycin as gonorrhoea therapy 
in the early 1980s (67). 
The reports of fluoroquinolone resistance had been arising during the period of 1980s to 1990s. 
It is well known that fluoroquinolones fail to recognise enzyme targets which are DNA gyrase 
and topoisomerase IV (67). Mutations of gyrA caused a missing target of a quinolone, while 
parC modified topoisomerase IV further inhibiting quinolone bindings (74). The bactericidal 
effect of quinolone was no longer used in many parts of the world by mid of the 2000s (67). 
Azithromycin was used as the treatment of gonorrhoea in the mid-1980, but the first report of 
resistance appeared ten years later in Latin America (75). The bacteriostatic effect of macrolide 
is promoted by binding with 50S ribosomal subunit, thus interfering with bacterial polypeptide 
productions (67). However, several mutations in 23S rRNA, mtrR and erm genes subsequently 
modifies the ribosomal target, blocking the binding system of macrolides (76). The rapid 
increase of macrolide MIC occurred due to efflux pump overexpression, involving some 
systems of MtrCDE, MacAB mef-encoded efflux pumps (76). The massive use of azithromycin 
for gonorrhoea treatments might increase azithromycin MIC in the future (67).  
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The third generation cephalosporins, either oral cefixime or injectable ceftriaxone, nowadays 
the most reliable single treatment for gonorrhoea (65). However, a great concern emerged once 
the first gonococcal extended drug resistance (XDR) strain towards injectable ceftriaxone was 
reported in Japan in 2012 (77). The ceftriaxone-resistance case in Japan was due to strain H041 
whilst a different strain (F89) accounted for three subsequent infections in France (78) and 
Spain (79),  A decade earlier, several studies had reported evidence of a high prevalence of 
treatment failure of cefixime (80-82).  
The mechanism of cephalosporin resistance involves the penA gene mutations encoding 
penicillin-binding protein 2 (PBP-2), the drug target of action (65). One process of 
cephalosporin resistance is initiated with the contribution of commensal Neisseria species in 
forming the mosaic penA gene (83). The mosaic penA allele causes mutations in the amino acid 
arrangements of PBP-2, i.e. G545S, I312M, and V316T (83). This process describes the 
decreased susceptibility of cefixime which is commonly found in oro-pharyngeal gonorrhoea, 
where other Neisseria populations are commonly found (65, 80). Meanwhile, mutations in the 
non-mosaic penA allele were associated with an increased MIC in both ceftriaxone and 
cefixime (78). These mutations cause amino acid alterations in PBP-2 specifically positions 
501, i.e. A501V, A501T and A501P. Mutations in G542S, P551S, and P551L positions 
promoting additional changes of PBP-2 are related to the antimicrobial resistance of 
ceftriaxone (78, 84, 85). Furthermore, the influx and efflux abnormalities due to penB and mtrR 
resulted in decreased susceptibility of cephalosporin (67).  
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2.1.2 Chlamydia trachomatis 
Chlamydia trachomatis is a small obligate intracellular bacterium (0.5 µm) in the form of an 
intracellular parasite (93).  There are eleven pathogenic species of chlamydia which have been 
identified to cause diseases either in humans or animals (94). Of this species group, two 
important pathogens that infect humans are CT and C. pneumoniae. The strain of CT is divided 
into three biovars which subsequently consist of serovars. Serovars A-C is a pathogenic group 
of bacteria that causes trachoma, a common cause of non-congenital blindness disease in 
several developing countries. In contrast, serovars D-K cause the genital infections and this is 
the most prevalent bacterial STI globally (94). In addition to these D-K serovars, L1-L3 serovar 
of chlamydia also leads to another type of STI called lymphogranuloma venereum (LGV). The 
LGV serovars are known as lymphotropic strains which are able to cause both local genital 
skin lesions and blockage of lymphatic drainage systems (95). 
Chlamydia trachomatis has a peptidoglycan free cell wall and is reportedly susceptible to 
various antimicrobial agents (96). In human genital tracts, CT will invade columnar epithelial 
cells in mucosal tissue, and often neighbouring macrophages. 
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The invasion of chlamydia causes urethritis in men and cervicitis in women (100). Undetected 
and untreated cases can lead to ascending genital tract infections, causing some severe 
sequelae, including pelvic inflammatory disease, infertility and ectopic pregnancy in women 
predominantly (94).
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2.1.3 Mycoplasma genitalium 
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2.2 Epidemiology of Bacterial STIs among MSM 
2.2.1 Global epidemiology of bacterial STIs 
Sexually transmitted infections are still one of the biggest burdens of acute illness for people 
living in both developing and developed countries. Based on World Health Organization 
(WHO) data in 2012, the estimated global prevalence of chlamydia among women 15-49 years 
old was 4.2%, gonorrhoea (0.8%), and syphilis (0.5%), while the prevalence among men was 
slightly lower with 2.7%, 0.6%, and 0.5%, respectively (22). The WHO also estimated that 
there were 214.6 million new cases in 2012, as follows: chlamydia (131 million), gonorrhoea 
(78 million), and syphilis (6 million) (22). New cases of chlamydia were higher in women (68 
million) than men (62 million), while the incidence among men was higher for gonorrhoea (44 
million vs 34 million) and syphilis (2.8 million vs 2.7 million).  
 
Source: "Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, et al. (2015) Global Estimates of the Prevalence and Incidence 
of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLOS ONE 10(12): e0143304. 
https://doi.org/10.1371/journal.pone.0143304 
Figure 2.5. The estimated global incidence of selected bacterial STIs among men in 2012 by 
regions (in million) 
Chlamydia represents the most frequent new case found in men, especially in Western Pacific 
(33 million). Western Pacific region had also the highest number of new gonorrhea cases (21 
million), followed by South East Asia (8 million). Chlamydia incidence was found to be quite 
high (7 million) in the Region of America, South-East Asia, and Eastern Mediterranean. The 
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case of syphilis was predominantly found in Africa region (1 million). Europe constituted the 
only area with a relatively low incidence of chlamydia, gonorrhea, and syphilis (22). 
In the past, before the introduction of testing for CT, gonococcal infection and syphilis were 
the two most important bacterial STIs and their prevalence has been measured for many 
decades in those countries with longstanding STI surveillance systems. From 1960 onwards, 
the STI endemic continued to rise for two decades in parallel to the growth of sexual revolution 
and following the introduction of contraceptives for birth control (142). The initial reporting of 
the Acquired Immunodeficiency Syndrome (AIDS) among gay men in 1980, and the 
subsequent identification of HIV as the causative agent, led the development of public health 
interventions in MSM and other at-risk communities to control HIV transmission in the face 
of growing AIDS-related deaths. The condom campaign and sexual health promotion activities 
were widely organised in many settings. The use of condoms as an option for the HIV/STI 
prevention reached its heyday during the mid- and late 1980s. However, the discovery, 
introduction and subsequent widespread use of antiretroviral therapy for HIV resulted in a 
decrease of safe sex practices, followed by increases in the prevalence of many STIs, including 
gonorrhoea and syphilis. The introduction of other non-condom HIV risk-reduction strategies 
such as serosorting, strategic positioning and the use of current biomedical approaches such as 
post-exposure prophylaxis (PEP), pre-exposure prophylaxis (PrEP) and treatment as 
prevention (TasP) have further led some to abandon use of condom with resulting increased 
STI transmission, particularly among MSM (143) 
2.2.2 Epidemiology of Bacterial STIs in Australia 
In Australia, the 2017 Annual Surveillance Report on HIV/AIDS, Viral Hepatitis & Sexually 
Transmissible Infections states that chlamydia is the most prevalent bacterial STI with 71,751 
cases, followed by gonorrhoea with 23,887 cases, and syphilis with 3,367 cases in 2016 (3). 
The annual number of notifications of gonorrhoea and syphilis had raised significantly from 
15,786 cases and 1,991 cases in 2015, respectively (4). Urban MSM constitute one of the two 
key populations associated with the high STI incidence in Australia, the other being 
heterosexual indigenous communities in remote areas of the country (3, 4). Among selected 
key populations, the incidence of gonorrhoea was increased among gay and bisexual men either 
HIV-positive or HIV-negative over the past five years (2010-2016), but the trend was relatively 
unchanged among female sex workers (3)  
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Based on distribution of bacterial STI by anatomical site, non-urethral infections are more 
prevalent among MSM (144, 145). Ano-rectal cases of chlamydia and gonorrhoea represent a 
major proportion of the total diagnoses (144). However, the rate of oro-pharyngeal gonorrhoea 
within MSM has been increasing even more rapidly in Australia (145). It has been proposed 
that oro-pharyngeal gonorrhoea may contribute to the higher incidence of asymptomatic cases 
(145, 146). In all populations, 65% of chlamydia diagnoses were detected in asymptomatic 
patients, 61% of infectious syphilis and up to 65% of gonorrhoea were also notified from 
asymptomatic individuals (5). The proportion of asymptomatic cases was higher among HIV-
positive gay and bisexual men in all three STIs (5). In the future, the proportion of MSM with 
asymptomatic STIs might continue to rise as a result of increased sexual activity involving 
oral-oral, penile-oral and penile-anal contacts, particularly as condom use is declining in the 
new era of HIV biomedical prevention (7, 147). Kissing, fellatio and rimming are three popular 
sexual activities practised by MSM, all of which may accelerate gonorrhoea spread through 
saliva (148, 149). According to the Australian Collaboration for Coordinated Enhanced 
Sentinel Surveillance (ACCESS) report for New South Wales (NSW) in 2015, the positivity 
of oro-pharyngeal gonorrhoea increased from 2% in 2007 to 7% in 2014 (250% increase) and 
urethral gonorrhoea increased from 1% in 2007 to 3% in 2014 (5). The positive gonorrhoea of 
ano-rectal swabs raised from 2% (2007) to 6% (2014), but had decreased from 8% in 2012 
(Figure 2.6). 
 
Source: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood 
Borne Viruses (ACCESS): New South Wales STI Report 2007-2014 
Figure 2.6. The trend of positive gonorrhoea swabs (%) by anatomic sites from 2007-2014 
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In Australia, recommendations for MG screening are still limited, and there are no MG in the 
routine STI surveillance program reports. A study in South Australia showed that as much as 
8.1% of dysuria among men was caused by MG (150). This pathogen, moreover, plays a 
significant role in the incidence of bacterial co-infection and is not infrequently detected in 
patients presenting with dysuria/urethral discharge due to chlamydial or gonococcal infections 
(150, 151). Within the MSM population, the incidence of bacterial STI co-infection may vary 
from 3 to 15% and has a high correlation with increased risk of HIV transmission (152-154).  
2.2.3 Asymptomatic bacterial STIs in MSM populations 
(5)
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The 
increased diagnosis of non-urethral infections among MSM is claimed as the success of STI 
program in Australia to capture asymptomatic men.   
2.3 The role of bacterial STIs in HIV transmission and acquisition 
Both epidemiologic and clinical evidence have proven the importance of STIs as co-factors 
which increase HIV transmissions, particularly in terms of HIV acquisition (160). Genital ulcer 
diseases (GUD) such as symptomatic syphilis and genital herpes have been previously known 
to enhance the opportunity for contact between HIV and its cellular targets (161). However, 
some non-ulcerative bacterial STIs also induce the HIV acquisition. A systematic review 
illustrated some common bacterial STIs such as gonorrhoea and chlamydia might double the 
risk of HIV transmission among the general population (162). This risk ratio is found to be 
higher among MSM (163).    
There are at least two possible mechanisms to describe the effect of STIs on facilitating HIV 
transmission. First, the presence of STI pathogens triggers the local inflammatory response and 
mucosal membrane disruption within the genital tissue, thus providing HIV entry points as 
shown in symptomatic genital herpes and syphilis (164). Secondly, for HIV infected 
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individuals, bacterial STIs such as gonorrhoea or chlamydia enhance the recruitment of active 
CD4 cells to the genital tract which can increase the concentration of HIV-RNA in semen or 
other genital fluids (162, 164). A study in Malawi reported that clients with urethral gonorrhoea 
had eightfold higher HIV-RNA in their semen (165). Repeated gonococcal infection is counted 
as a significant risk factor for subsequent development of HIV infection (166). 
Among MSM, the risk of HIV acquisition is higher among those who have ano-rectal infections 
with more receptive anal sex practices (167). The risk of HIV acquisition among MSM infected 
with ano-rectal gonorrhoea was three-fold higher than non-infected MSM (167). However, 
both ano-rectal gonorrhoea and chlamydia do not significantly increase the risk of HIV 
transmission. Anal swab testing of MSM who are positive for ano-rectal CT/NG showed no 
increase of HIV RNA (168). The high-risk acquisition among MSM is more relevant in the 
context of high-risk sexual behaviours, such as having unprotected anal sex with multiple 
partners (167). In contrast, the high incidence of oro-pharyngeal gonorrhoea in MSM is not 
correlated with HIV infection (169). A recent systematic review reported that individuals 
infected with MG were more likely to be HIV infected (170). A study among women with 
cervicitis proposed a different way of HIV RNA shedding in MG infection that involves 
chronic immune cells. While gonorrhoea and chlamydia increase the HIV shedding by 
generating an acute immune response, HIV within MG-infected cells was found in chronic 
immune cells, which may have a longer duration of infectious phase (171).  
2.4 Influential predictors related to the prevalence of bacterial STIs 
2.4.1 HIV-positive MSM  
45 
 
 
 
46 
 
 
Source: the Kirby Institute. Annual Surveillance Report 2017: HIV, viral hepatitis and sexually transmissible infections in Australia 
A longer duration of STI treatment may be required to treat STIs in some 
HIV-positive individuals, in whom persistent 
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The 
Australian Study of Health and Relationships (ASHR), in 
2.4.2 MSM using PrEP  
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2.4.3 Young MSM 
2.5 Public Health Prevention of Bacterial STIs in MSM 
High-risk sexual behaviours potentially put individuals at risk for STIs, unplanned pregnancy, 
and early sexual relationship. The high-risk sexual behaviour has a broad meaning, but can be 
defined as follows (211): 
• Unprotected intercourse without barriers (i.e. condom) except in monogamous 
relationships 
• Unprotected oral sex except in a long-term monogamous relationship 
• Early sexual activity (before 18 years old) 
• Having multiple sex partners or having a high-risk sexual partner who has multiple sex 
partners in his/her own right 
• Engaging in anal sex, or having a partner who does, except in monogamous relationship 
• Having sex with injecting drugs users 
• Trading sex (sex for money)  
In many countries, MSM are among those who tend to practice high-risk sexual behaviours, 
such as high frequency of anal receptive sex, unprotected oral sex, multiple partners, and low 
levels of condom use (195). A primary prevention strategy must include elements which lead 
50 
 
to improved STI control among MSM. A comprehensive approach to STI prevention should 
be based on five main strategies (212): 
• Accurate assessment of high-risk population followed by comprehensive education and 
counselling towards STI prevention   
• Vaccination of individuals at risk 
• Screening of both asymptomatic and symptomatic people for STIs 
• Effective diagnosis, treatment, counselling, and follow-up of infected individuals 
• Effective contact tracing among sex partners who at risk of STIs  
In general, STI prevention can be divided into two major components, one with focuses on 
sexual behaviour change in educational settings and one which focuses on the use of 
biomedical interventions for prevention purposes. 
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Table 2.1 Vaccine candidates for chlamydia  
 
Source: Poston, Taylor B., Sami L. Gottlieb, and Toni Darville. "Status of Vaccine Research and Development of Vaccines for Chlamydia 
Trachomatis Infection." Vaccine (2017). 
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Chapter 3  
Methods  
 
This chapter describes the study characteristics and outlines how the study was conducted. 
Details covered in this section are the study design, sample size, study period, study procedure, 
data collection process, and data analysis. The method was designed to achieve the study 
objectives about the prevalence of bacterial STIs among asymptomatic MSM and selected 
factors in this population associated with the positive diagnosis of bacterial STIs.      
3.1 Study design  
This research was an observational study with a quantitative analysis approach. The 
quantitative analysis calculated the prevalence of three bacterial STIs in asymptomatic MSM 
and also measured the factors or predictors of participants which influence the positivity of 
bacterial STI diagnosis, specifically Chlamydia trachomatis, Neisseria gonorrhoeae, and 
Mycoplasma genitalium. All the data were collected in Western Sydney Sexual Health Clinic, 
Parramatta, New South Wales for the period between July and September 2017. The data 
collection process was performed using a retrospective cross-sectional approach. The 
researcher reviewed both the print out of the computer-assisted self-interview (CASI) data 
provided routinely by patients using the WSSHC’s Express Clinic service for asymptomatic 
patients and laboratory testing result sheets.  
3.2 Sampling method 
3.2.1 Sample criteria 
The inclusion factor of participants in this study was determined by reviewing literature and 
adjusting to situations in the research setting. Participants were limited to asymptomatic HIV-
uninfected MSM aged 18 years old and over who was attending the Express clinic service in 
WSSHC and undergoing onsite STI screening between 1 February and 31 May 2017. This 
study did not manage a recruitment process as data was already recorded in both hardcopy and 
electronic notes. Any MSM reporting any STI symptoms based on clinical note review, or 
known to be HIV seropositive, were excluded and managed outside of the WSSHC’s Express 
service. 
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3.2.2 Sample size 
To calculate the minimum sample size, we used expected prevalence estimations for Neisseria 
gonorrhoeae (NG), Chlamydia trachomatis (CT) and Mycoplasma genitalium (MG) based on 
existing data within WSSHC’s sexual health information program (SHIP) for the Express clinic 
(NG/CT) and Senior Staff Specialist-based assumptions (MG). Currently, the SHIP diagnostic 
disease categories do not include MG, so the expected MG prevalence has to be estimated by 
Prof. David Lewis, Director WSSHC, based on his clinical experience.   
According to the SHIP database, 580 MSM attended the WSSHC Express clinic to undertake 
routine STI testing in the six-month period of November 2016 to April 2017. In that period, 
the number of MSM who tested positive for CT and NG were 80 (14%) and 69 (12%), 
respectively. Based on that prevalence, an STI Senior Specialist (Prof. David Lewis) estimated 
that the MG prevalence among asymptomatic MSM would be approximately 10%. Using a 
sample size formula for a cross-sectional study (248), with 95% CIs and a 0.05 limit of error, 
the sample sizes for the three STIs prevalence studies would be 139 (CT), 163 (NG), and 185 
(MG) MSM respectively. The formula used for these calculations were: 
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =  𝑍𝑍1−𝛼𝛼 2⁄  2𝑆𝑆𝑆𝑆2
𝑑𝑑2
 
𝑍𝑍1−𝛼𝛼 2⁄ = 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑑𝑑𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑛𝑛𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑣𝑣𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 
SD = standard deviation of variable from previous study or assumption 
d = absolute error of precision   
 
Therefore, this study needed to enrol approximately 200 patients to obtain a statistically sound 
prevalence result. After summarising the total clients attending Express clinic during the course 
of study, we were able to include 307 participants in the study. 
3.3 Study settings 
The study was conducted in one setting which was WSSHC in Parramatta, New South Wales. 
The WSSHC is a clinic where people living in Western Sydney and surrounds attend for health 
services related to sexual health and HIV/STI issues. This venue provides a comprehensive 
HIV/STI screening package with either regular or brief sexual health consultation. Around 
twenty people book for the Express clinic service, which caters for asymptomatic people 
wanting HIV/STI screens, each day. MSM clients who attended the Express clinic during the 
four-month period of February to May 2017 were included as all MSM reviewed in this time 
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were additionally screened for MG as part of an MG prevalence study in MSM that was on-
going at the same time.  
3.4 Study procedures 
This study used secondary data by reviewing medical records and electronic notes. Patient 
information obtained via CASI technology and STI lab results had been saved in clinic files 
prior to the data collection process.  
3.4.1 Overview of the WSSHC Express service 
To measure the prevalence of bacterial STIs, we undertook a retrospective cross-sectional 
investigation by recording the existing STI screening results for asymptomatic MSM attending 
WSSHC’s routine Express service. At the Express clinic, patients enter their own demographic, 
behavioural and clinical status data into CASI machines that are present in the clinic waiting 
area. This data entry process results in generation of a printed history sheet which the clinic 
nurse routinely checks prior to filing in the patients’ notes. A nurse then undertakes further 
discussion and advises the client before routine STIs screening. Any patients reporting 
symptoms during the nurse review are transferred from Express to see a doctor elsewhere in 
the clinic. Also, the nurses routinely enter data on WSSHC’s SHIP database, which also 
receives electronic results from the diagnostic microbiology laboratory at Westmead Hospital. 
The Express clinic machine contains a question about HIV status. Clients admitting their 
positive HIV status will automatically exit from Express clinic and will be referred to regular 
clinics. In this study, HIV-positive MSM were solely excluded. 
3.4.2 STI screening procedures 
Within the Express clinic service, the nurse collects blood for HIV and syphilis serological 
screening; for those MSM unsure of their hepatitis A and B vaccination history, additional tests 
are requested for pre-vaccination serological testing. The nurse collects a throat swab from all 
MSM attending the service, and then patients collect their own ano-rectal swab and first-pass 
urine specimens in the clinic bathroom. Urine, ano-rectal, and oropharyngeal samples are 
routinely tested for chlamydia. As the commercial molecular assay used to detect chlamydial 
infection is duplex in nature (i.e. it simultaneously detects NG, if present), there is an 
arrangement with the local laboratory that any positive NG results will be relayed to the clinic, 
even if not requested. In order to reduce costs, a request to test only for chlamydial infection 
only is made for all urine specimens from asymptomatic MSM (on the basis that almost all 
gonococcal urethral infections would be symptomatic).  Since February 2017, all three patient 
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specimens (urine, ano-rectal and oro-pharyngeal) were additionally tested for MG as part of an 
on-going WSLHD study to determine MG prevalence among asymptomatic MSM 
[HREC/16/WMEAD/280; SSA/16/WMEAD/304; Dr Deborah Couldwell (PI), Prof. David 
Lewis (co-I), Dr Lukman Chandra (co-I)].  
A molecular nucleic acid amplification test (NAAT) is a standard technique to diagnose CT, 
NG, and MG in the referral lab. In Westmead Hospital, either CT or NG screening is processed 
in the BD ViperTM XTR system (Becton, Dickinson and Company, Sparks, Maryland State, 
the United States of America). More specifically, the test for CT is BD ProbeTecTM Chlamydia 
trachomatis (CT) Qx Amplified DNA Assay, and NG using BD ProbeTecTM Neisseria 
gonorrhoeae (QC) Qx Amplified DNA Assay. All positive NG specimens obtained from BD 
ProbeTech will be confirmed using BD MAX™ Neisseria gonorrhoeae (Becton, Dickinson 
and Company, Heidelberg, Germany). For the detections of MG, the lab uses MG 
ResistancePlusTM PlexPCR assay (SpeeDx Pty. Ltd, Sydney, NSW, Australia) which is also 
able to identify macrolide resistances of MG.  
3.4.3 Data Collection 
A retrospective review of both the CASI-derived hard copy clinic notes and the SHIP-based 
computerised records was undertaken to record the demographic, behavioural, and clinical 
status of patients on a study proforma. The patient data collected related to either the previous 
3 or 12 months, depending on the data element concerned in keeping with the CASI/SHIP 
database entries. Through both the SHIP database and hard copy notes, we obtained the 
following information: 
Table 3.1 List of patients’ information obtained during collecting data   
Risk factors Variable Category Notes 
Demographic 
factor 
Age group - < 30 
- 30+ 
 
 Country of birth - Australia 
- others 
 
 Main language at home - English 
- other 
 
Behavioural 
factor 
Sex orientation  - homosexual 
- bisexual 
Sex orientation in the 
last 12 months 
 Current regular partner - yes  
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- no 
 Number of sex partner  - 0 
- 1 
- 2-5 
- 6-10 
- 11+ 
In the last 3 and 12 
months 
 Condom use - no condom 
- sometimes 
- usually 
- always 
- “sometimes” means 
less than 50% of 
condom use at any 
sex 
- “usually” means 
more than 50% of 
condom use at any 
sex 
- Condom use in the 
last 3 and 12 months 
 Injecting drug use - yes 
- no 
 
Clinical factor Current PrEP status - on PrEP  
-  not on PrEP 
 
 No. of past STI episodes - nil 
- 1-3 
- 4-7 
- 8+ 
 
PrEP, pre-exposure prophylaxis; STI: sexually transmitted infection 
3.5 Data analysis 
The data were summarised using Microsoft Excel software 2013 and analysed with an SPSS 
(version 23.0; SPSS, IBM, Inc, Chicago, IL, USA) to generate results. We calculated the 
prevalence of NG, CT and MG infections by site and overall in the patient population based on 
positive laboratory results. The analysis measured the frequency and proportion of the positive 
results as compared with the total of screening tests undertaken among asymptomatic MSM 
attending the WSSHC Express Clinic over the defined data collection period. We also 
presented bacterial STI pathogen prevalence data by the site of infection (urethra, ano-rectum, 
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and oro-pharynx). This study enabled calculation of the percentage and frequency of 
NG/CT/MG co-infections. The prevalence would be presented in tables and graphs in the 
following Chapter.  
Cross-tabulations and analyses of associations (including regression analyses) were performed 
in SPSS. Bivariate cross-tabulations and Pearson’s chi2 test for independence were first 
assessed to identify any associations.  
The outcome of interest was composite variable of any of the three STIs at any anatomical sites 
of infection. A univariate logistic regression analysis was performed to assess the strength of 
individual associations between selected demographic, behavioural, and clinical factors, and 
the outcome of interest. Variables which were significantly associated with a positive STI 
diagnosis at significance level of p < 0.2, were considered for further multivariate regression 
analysis (249). Presented in Chapter 4 are odds ratios (OR) with 95% confidence intervals (CI) 
measured to identify which associations between patient risk factors and positive NG/CT/MG 
results were significant. 
3.6 Ethical considerations and expected outcome 
The researcher did not have access to patient identifiers. Data were analysed and presented in 
aggregated form. Data have been stored securely as required by Mr. Chung as an IT advisor in 
WSSHC. Informed consent forms were not attempted from participants as this study utilised 
retrospective data by reviewing patient files. The ethical clearance was sought from the 
Western Sydney Local Health District and consisted of Human Research Ethics Committee 
(HREC) and the Research Governance Office (RGO) approvals. The following reference 
number of the HREC ethic letter was LNR/17/WMEAD/239, and the reference number of 
RGO Site Specific Authorisation (SSA) letter was LNRSSA/17/WMEAD/264. Ethical 
approval from the University of Sydney was not required as the approval from the University 
accepts WSLHD HREC approval in lieu of a formal University application.  
The study will provide a useful understanding of the numbers of bacterial STIs diagnosed in 
the Express service and also provide insight into patient risk factors which may aid in health 
promotion activities by clinic staff. 
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3.7 Contextual framework 
 
Figure 3.1 Contextual framework 
3.8 Limitation of Methodology 
The process of obtaining important data from samples might be limited by the Express 
clinic/CASI machine settings. Respondents using the Express clinic facility will be faced with 
the previous set of questions whilst researchers were unable to alter the list due to external 
instalment process. This issue causes variables to be limited to the questions available in the 
CASI machine. 
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Chapter 4  
Results 
 
The records of 307 asymptomatic MSM who attended the WSSHC Express clinic during the 
study period were successfully reviewed. Basic data on demographics, sexual behaviours, and 
clinical characteristics of participants will be discussed in the first section of this chapter. 
Tables and figures then illustrate the prevalence of bacterial STI and co-infections cases. 
Finally, the outcomes of univariate and multivariate logistic regression analysis will be 
presented through separated tables. Two participants mentioning no sexual partners in the last 
three months were not included in the regression analyses due to the missing assessment of 
condom use. However, they were still involved in the calculation of prevalence rate. 
4.1 Basic data of participants  
4.1.1 Demographic characteristics 
Of the 307 samples of MSM, the age of participants was between 17 and 72 years old with a 
mean age of 32.5 years old. The median of samples is 29.0 with a standard deviation of 11.3. 
Table 4.1 Demographic characteristics of participants (n=307)  
Characteristics N (%) 
Age group  
- <20 years old 14 (4.6) 
- 20-29 144 (46.9) 
- 30-39 81 (26.4) 
- 40-49 39 (12.7) 
- 50+ 29 (9.4) 
Country of birth 
 
- Australia 177 (57.7) 
- other 130 (42.3) 
Main language at home 
 
- English 247 (80.5) 
- other 60 (19.5) 
 
Table 4.1 summarises the demographic characteristics obtained from 307 participants. Based 
on age groups, the majority of participants were categorised as young adults aged under 40 
years of age. Nearly half (46.9%) of total participants were MSM aged 20-29 years old, and 
one fourth (26.4%) were a group of 30-39 years old men. Adolescent MSM (<20 years old) 
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possessed the lowest proportion with only 4.6%, while the older groups aged 40-49 and 50+ 
had 12.7%, and 9.4%, respectively.  
The majority of MSM participants in this study were Australia-born (57.7%), while the rest 
130 men (42.3%) were immigrants who came from 40 different countries. The majority of 
MSM who born outside Australia were born in Asian countries, such as The Philippines (4.9%), 
China (4.2%) and India (3.6%). Based on WHO classification of global regions, participants 
were mainly originated from Western Pacific region with 61.6% in proportion (Figure 4.1). 
 
Figure 4.1 Birthplace of participants (%) by the WHO regions (n=307) 
A total of 28.7% of MSM were born in the Southeast Pacific region. While other regions such 
as Europe, Eastern Mediterranean, America, and Africa are in the range of 1-3% of the total 
participants. 
Most of the participants (80.5%) spoke English in their main language at home, while about 
one fifth preferred to converse in their native languages. The most popular non-English 
languages were Mandarin (6.8%), Vietnamese (2.6%) and Tagalog (1.9%). Few people still 
spoke languages from Eastern Mediterranean (Arabic, Assyrian and Dari), South Asian (Urdu, 
Hindi, Tamil and Nepali) and European (Spanish and Russian) regions.  
4.1.2 Sexual behavioural characteristics 
Data concerning participants’ sexual behaviours are summarised in Table 4.2. Several variables 
were analysed for the 307 participants, including sexual orientation, the presence or absence of 
a regular partner, the number of self-reported sex partners and condom use in the previous three 
months, as well as injecting drug status.    
Table 4.2 Sexual behaviours among participants (n=307) 
African
1.3%
American
2.3%
South-East Asia
28.7%
European
3.3%Eastern 
Mediterranean
2.9%
Western Pacific
61.6%
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Characteristics N (%) 
Sex orientation (last 12 months)  
- homosexual 264 (86.0) 
- bisexual 43 (14.0) 
Regular partner 
 
- yes 113 (36.8) 
- no 194 (63.2) 
Number of sex partner (last 3 months) 
 
- 0 2 (0.7) 
- 1 55 (17.9) 
- 2-5 155 (50.5) 
- 6-10 61 (19.9) 
- >10 34 (11.1) 
Condom use (last 3 months)a 
 
- no condom 53 (17.4) 
- sometimesb 67 (22.0) 
- usuallyc  82 (26.9) 
- always 103 (33.8) 
Injecting drug use 
 
- yes 10 (3.3) 
- no  297 (96.7) 
 a = two participants reporting no sex partners in the last three months could not be assessed for condom use 
b = less than 50% of using condoms at any sex 
c = more than 50% of using condoms at any sex  
Most MSM (264 men, 86.0%) confirmed that they only had sex with men whilst the remaining 
43 (14.0%) participants self-reported sex with both men and women (bisexual) in the last 12 
months. Around one third (36.8%) of participants had regular sex partners. Very few MSM 
self-reported injected drug use (3.3%). Approximately half of the MSM participants (155 men, 
50.5%) reported sexual contact with 2-5 partners in the previous three months. Almost one-
fifth of the MSM participants (61 men, 19.9%) reported 6-10 partners and a further 35 MSM 
(11.1%) reported more than ten partners over the same period. About one fifth (17.9%) of all 
MSM mentioned only have one partner, while two participants (0.7%) did not mention any sex 
partner within last three months. Consistent condom use was reported only by 103 MSM 
(33.8%), whilst 53 MSM (17.4%) reported that they had not used condoms for their sexual 
encounters in the previous three months. Two participants who reported no sexual partners in 
the last three months were excluded from condom use assessment.  
Table 4.3 Clinical characteristics of participants (n=307) 
Characteristics N (%) 
PrEP status  
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- on PrEP 165 (53.7%) 
- not on PrEP 142 (46.3%) 
No. of past STI episodes 
 
- 0 116 (37.8%) 
- 1-3 139 (45.3%) 
- 4-7 33 (10.7%) 
- 8+ 19 (6.2%) 
PrEP, pre-exposure prophylaxis; STI: sexually transmitted infection 
4.1.3 Clinical characteristics  
Table 4.3 illustrates characteristics of participants related to PrEP use as a biomedical HIV 
prevention program and the number of previous episodes of STIs reported by the MSM. Among 
participants, the proportion of MSM who used PrEP was slightly higher than the ones who did 
not (165 men, 53.7% compared to 142 men, 46.3%). Around one third (116 men, 37.8%) of all 
participants denied any history of STIs, while more MSM (139 men 45.3%) stated that they 
had at least one to three episodes of STI previously. Only 6.2% of the 307 MSM had 
experienced more than seven STI episodes. 
4.2 Prevalence of Bacterial STIs  
4.2.1 Summary of bacterial STI prevalence  
Bacterial STI diagnoses were calculated from the number of positive results of laboratory 
testing undertaken for CT, NG, and MG. The laboratory results of all 307 MSM were 
successfully identified from medical files. MSM were screened at three sites, specifically the 
urethra (first-pass urine specimen), oro-pharynx (oro-pharyngeal swab) and ano-rectum (ano-
rectal swabs), for each of these three bacterial infections. Table 4.4 indicates that as many as 
82 participants (26.7%) were diagnosed with at least one infection at one site, while 225 
(73.3%) participants showed no evidence of any of these three bacterial STIs. Overall, there 
were 38 (12.4%) MSM infected with MG, 35 (11.4%) MSM infected with CT and 27 (8.8%) 
MSM infected with NG. 
Table 4.4 Proportion of individuals with a positive diagnosis of bacterial STIs (n=307) 
Test results N % 95% Confidence Interval 
Positive 82 26.7 22.1% to 31.7% 
Negative 225 73.3 68.3% to 77.9% 
Table 4.5 describes the frequency of total, single and mixed bacterial STI diagnoses among the 
82 MSM diagnosed with a bacterial STI. The most common single infection was MG (28 men, 
34.1%), followed by CT (21 men, 25.6%) and NG (17 men, 20.7%). A total of 14 (40.0%) 
MSM with chlamydial infection were co-infected with other pathogens (six with NG alone, six 
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with MG alone and two with both NG and MG). Nine (24.3%) of the MSM with MG infections 
had co-infections with either CT alone (six men) or NG alone (one man) or both CT and NG 
(two men). Ten (37.0%) MSM with gonococcal infections were co-infected with CT alone (six 
men), MG alone (one man) or both CT and MG (two men). All mixed infections were identified 
in the same anatomic site.   
Table 4.5 Frequency of total, single and mixed bacterial STI diagnoses among MSM diagnosed 
with a bacterial STI (n=82) 
Pathogen identified N (% of overall) 
Total CT infections 
Total NG infections 
Total MG infections 
Single CT infections 
35 (42.7) 
27 (32.9) 
37 (45.1) 
21 (25.6) 
Single NG infections 17 (20.7) 
Single MG infections 28 (34.1) 
Mixed CT/NG infections 6 (7.3) 
Mixed CT/MG infections 6 (7.3) 
Mixed NG/MG infections 1 (1.2) 
Mixed CT/NG/MG infections 2 (2.4) 
CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; MG, Mycoplasma genitalium  
4.2.2 Prevalence of bacterial STI by anatomical sites 
Of the total 307 urine, 307 ano-rectal, and 307 oro-pharyngeal samples processed, the 
prevalence of bacterial STI was summarised in this table 4.6 below.  
Table 4.6 Prevalence of bacterial STI by anatomical sites (n=307) 
 CT NG MG 
Specimen site  n (%) 95% CI n (%) 95% CI n (%) 95% CI 
Urine (n=307) 7 (2.3) 0.7 to 3.9 1 (0.3) 0.01 to 1.0 9 (2.9) 1.2 to 5.2 
Ano-rectal (n=307) 30 (9.8) 6.5 to 13.0 14 (4.6) 2.6 to 6.6 29 (9.4) 6.2 to 12.7 
Oro-pharyngeal (n=307) 3 (1.0) 0.04 to 2.3 17 (5.5) 2.9 to 8.1 0 0 
 95% CI, confidence interval; CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; MG, Mycoplasma 
genitalium  
Three most frequent diagnoses found among asymptomatic MSM were ano-rectal CT with a 
prevalence of 9.8% (95% CI: 6.5 to 13.0), ano-rectal MG with 9.4% (95% CI: 6.2 to 12.7), and 
oro-pharyngeal NG with 5.5% (95% CI: 2.9 to 8.1). Figure 4.2 below illustrates the comparison 
of bacterial STI diagnosis prevalence from those three pathogens and three specimens.    
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CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; MG, Mycoplasma genitalium  
Figure 4.2 Comparison of the prevalence of three bacterial STIs (n=307) 
While positive CT and MG results were majorly found in ano-rectal sites, these pathogens were 
relatively uncommon in either urine or oro-pharyngeal samples. Of the 307 MSM, only 2.3% 
(95% CI: 0.7 to 3.9) and 1.0% (95% CI: 0.04 to 2.3) had CT detected in urine and throat 
respectively. The similar trend was reported among MG diagnosis results, where only 2.9% of 
urethral samples and none (0%) of oro-pharyngeal samples were positive for MG. Meanwhile, 
the diagnosis of NG was more frequent at oro-pharyngeal (5.5%), and ano-rectal sites (4.6%) 
(95% CI: 2.6 to 6.6). Not unsurprisingly, given the symptomatic nature of urethral gonorrhoea, 
only one person or 0.3% (95% CI: 0.04 to 2.3) of asymptomatic MSM was positive for urethral 
NG.  
 
 
Figure 4.3 Distribution of infection identified from three anatomical sites (n=307) 
2.3%
9.8%
1.0%
0.3%
4.6%
5.5%
2.9%
9.4%
0.0%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
Prevalence (%)
1.8%
7.9%
2.2%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
9.0%
urethral ano-rectal oro-pharyngeal
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Figure 4.3 indicated that the prevalence of asymptomatic infections of ano-rectum (7.9%) was 
threefold higher than asymptomatic infections at the two other sites (oro-pharyngeal, 2.2% and 
urethral, 1.8%). Compared to urethral infections, the relative proportion of non-urethral STIs 
(ano-rectal and oro-pharyngeal sites) was by far more common among asymptomatic MSM as 
shown in figure 4.6 below.   
Figure 4.4 Relative proportions of urethral and non-urethral infections among asymptomatic 
MSM diagnosed with bacterial STIs (n=82) 
Figure 4.4 shows a significant difference in the proportion of non-urethral and urethral isolates. 
Non-urethral infections represent 84.5% of all positive results, while urethral cases were only 
15.5%.  
4.2.4 Prevalence of co-infections by sites of infection 
There were 15 (4.9%) cases of co-infections found among 307 participants tested for CT, 
NG, and MG. In this study, the term “co-infection” meant two or more pathogens identified 
at the same anatomical site.  
Table 4.7 Prevalence of co-infections (n=307) 
Pathogens Urethral n (%) 95% CI Ano-rectal n (%) 95% CI Oro-pharyngeal 
n (%) 
95% CI 
CT/NG 0 0 5 (1.6) 0.3 – 2.6 1 (0.3) 0.01–1.1 
CT/MG 0 0 6 (2.0) 0.7 – 3.4 0 0 
NG/MG 0 0 1 (0.3) 0.01–1.1 0 0 
NG/CT/MG 0 0 2 (0.7) 0.05-2.0 0 0 
CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; MG, Mycoplasma genitalium  
84.5%
15.5%
non-urethral urethral
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Table 4.7 shows that vast majority of co-infections were at the ano-rectal site, specifically six 
CT/MG co-infections (2.0%, 95% CI: 0.7 to 3.4) and five CT/NG co-infections (1.6%, 95% 
CI: 0.3 to 2.6). Co-infections involving NG and MG were less frequently reported at the ano-
rectal site (0.3%, 95% CI: 0.01-1.1). Two men (0.7%) had all three bacterial pathogens detected 
at the ano-rectal site. There was only one MSM participant with evidence of co-infection at the 
oro-pharyngeal site (a mixed CT/NG infection) whilst there were no co-infections detected in 
the urine specimens of the 307 asymptomatic MSM who were tested.  
4.3 Factors associated with bacterial STI prevalence 
The outcome of interest in this study is any positive results of three bacterial STIs (CT, NG, 
MG) at any sites of infection (urethral, ano-rectal, oro-pharyngeal). Prior to regression 
analyses, we present a cross-tabulation describing the diagnosis of bacterial STI and selected 
risk factors identified from participants 
4.3.1. Proportion of bacterial STI diagnosis by selected risk factors 
Table 4.8 provides the proportion of bacterial STI diagnosis based and this association with 
selected risk factors. The Pearson's chi2 test for independence determined the significance of 
associations through p-value.  
Table 4.8 Bivariate cross-tabulation of bacterial STI diagnosis and selected risk factors. 
variable diagnosis p-value 
positive (%) negative (%) 
Age group    
- <30 44 (53.7) 114 (50.7) 0.64 
- 30+ 38 (46.3) 111 (49.3)  
COB    
- Australia 43 (52.4) 134 (59.6)  
- Others 39 (47.6) 91 (40.4) 0.26 
Sex orientation    
- Homosexual 67 (81.7) 197 (87.6)  
- Bisexual 15 (18.3) 28 (12.4) 0.19 
Regular partner    
- Yes 26 (31.7) 87 (38.7)  
- No 56 (68.3) 138 (68.3) 0.26 
No of sex partner (3mo)    
- 0 1 (1.2) 1 (0.4) 0.001 
- 1 14 (17.1) 41 (18.2)  
- 2-5 29 (35.4) 126 (56.0)  
- 6-10 20 (24.4) 40 (17.8)  
- 11+ 18 (22.0) 17 (7.6)  
Condom use (3mo)a    
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- no condom 15 (18.5) 38 (17.0) 0.002 
- sometimesb 29 (35.8) 38 (17.0)  
- usuallyc 20 (24.7) 62 (27.7)  
- always 17 (21.0) 86 (38.4)  
Injecting drug use    
- yes 4 (4.9) 6 (2.7) 0.33 
- no  78 (95.1) 219 (97.3)  
PrEP status    
- on PrEP 57 (69.5) 108 (48.0) 0.001 
- not on PrEP 25 (30.5) 117 (52.0)  
No. of past STI episodes    
- nil 19 (23.2) 97 (43.1) 0.006 
- 1-3 43 (52.4) 96 (42.7)  
- 4-7 11 (13.4) 22 (9.8)  
- 8+ 9 (11.0) 10 (4.4)  
COB, country of birth; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection; mo, month 
aTwo participants not mentioning any sex partner in the last three months were excluded due to missing condom use 
assessment  
bless than 50% of using condoms at any sex 
cmore than 50% of using condoms at any sex  
In the table above, it appears that the proportion of positive results is relatively equal in the 
categories within age group and country of birth. The proportion of young MSM with bacterial 
STI diagnosis (<30 years old) was 53.7%, only slightly higher than MSM aged more than 30 
years old (46.3%). The proportion of positive diagnosis was also relatively similar in 
Australian-born MSM (52.4%) and non-Australian born (47.6%). In the other variables, 
bacterial STI diagnoses were more frequent among homosexuals (81.7%) than bisexual men, 
MSM without a regular partner (68.3%) than those with a regular partner, MSM who do not 
inject drugs (95.1) than those who inject drugs, and MSM currently on PrEP (69.5%) than those 
who do not use PrEP. Diagnosis of bacterial STI was also more common in MSM who had one 
to three episodes of previous STIs (52.4%), sometimes using a condom (35.8%) in the last three 
months and MSM who engaged with two to five sex partners (35.4%) in the last three months. 
However, based on Pearson Chi-square test, only the following variables, such as condom use, 
number of partners, PrEP status, and past STI episodes had statistical significance (Table 4.8). 
4.3.2 Regression analyses of bacterial STI diagnosis and selected risk factors        
Both univariate and multivariate analysis was performed to measure the association of any 
bacterial STI diagnosis with selected risk factors. The Table of univariate analyses shows 
several factors such as the number of partners, condom use, PrEP status, and a number of past 
STI episodes which showed significance with p<0.05 (Table 4.9). Nevertheless, we based on 
the p-value cut-off point of 0.2 to include several important variables into the model. Therefore, 
five variables were eventually analysed in these multivariable models (Table 4.9). 
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Table 4.9 Univariate and multivariate analysis of bacterial STI diagnosis by selected risk 
factors . 
variable diagnosis N 
(%) 
UOR (95%CI) p-value AOR (95%CI)a p-
value 
Age group      
- <30 44 (53.7) 1.13 (0.68 - 1.88) 0.64   
- 30+ 38 (46.3) 1    
Country of birth      
- Australia 43 (52.4) 1    
- Other 39 (47.6) 1.34 (0.80 - 2.22) 0.26   
Sex orientation      
- Homosexual 67 (81.7) 1    
- Bisexual 15 (18.3) 1.58 (0.79 - 3.13) 0.19 1.12 (0.66 - 3.15) 0.76 
Regular partner      
- Yes 26 (31.7) 1    
- No 56 (68.3) 1.36 (0.79 - 2.32) 0.26   
No of sex 
partner (3mo) 
     
- 0 1 (1.2) 2.93 (0.17 – 49.9) 0.46 n/aa  
- 1 14 (17.1) 1    
- 2-5 29 (35.4) 0.67 (0.33 - 1.40) 0.29 0.53 (0.25 - 1.16) 0.11 
- 6-10 20 (24.4) 1.46 (0.65 - 3.29) 0.35 0.91 (0.37 - 2.18) 0.82 
- 11+ 18 (22.0) 3.10 (1.26 - 7.62) 0.01 1.55 (0.56 - 4.25) 0.39 
Condom use 
(3mo) 
     
- always 17 (21.0) 1    
- no condom 15 (18.2) 1.99 (0.90 - 4.41) 0.09 1.31 (0.55 - 3.14) 0.54 
- sometimesb 29 (35.8) 3.86 (1.89 - 7.85) <0.001 2.39 (1.05 - 5.51) 0.04 
- usuallyc 20 (24.7) 1.63 (0.79 - 3.37) 0.22 1.26 (0.57 - 2.78) 0.56 
Injecting drug 
use 
     
- yes 4 (4.9) 1.87 (0.52 - 6.81) 0.34   
- no  78 (95.1) 1    
PrEP status      
- on PrEP 57 (69.5) 2.47 (1.44 - 4.23) 0.001 1.46 (0.77 - 2.74) 0.24 
- not on PrEP 25 (30.5) 1    
No. of past STI 
episodes 
     
- nil 19 (23.2) 1    
- 1-3 43 (52.4) 2.29 (1.24 - 4.21) 0.008 1.92 (1.01 - 3.62) 0.04 
- 4-7 11 (13.4) 2.55 (1.06 - 6.12) 0.03 1.67 (0.65 - 4.28) 0.29 
- 8+ 9 (11.0) 4.59 (1.65 - 12.81) 0.004 2.67 (0.88 - 8.14) 0.08 
COB, country of birth; UOR, unadjusted odds ratio; AOR, adjusted odds ratio; 95% CI, confidence interval; PrEP, pre-
exposure prophylaxis; STI, sexually transmitted infection; mo, month; n/a, not any  
aTwo participants were excluded in the multivariate analysis due to reporting no sex partners and missing condom use 
assessment in the last three months 
bless than 50% of using condoms at any sex 
cmore than 50% of using condoms at any sex 
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Within both univariate and multivariate analysis, the diagnosis of bacterial STIs was 
significantly and consistently related to factors of condom use and past STI history. In the 
univariate analysis, diagnosis of STI was three times more common among MSM who 
sometimes used a condom during sexual intercourse than the consistent condom users with 
unadjusted odds ratio (UOR)=3.86, 95% CI: 1.89 to 7.85, p=0.001. Table 4.9 also indicated a 
significant result of past STI history in univariate analysis. The risk of having STI increased 
continuously with the number of past STI episodes. Compared to participants who had no 
previous STI episodes, the risk of having a bacterial STI detected was double among MSM 
experiencing 1-3 STI episodes (UOR=2.29, 95% CI: 1.24 to 4.21, p<0.01) and 4-7 STI episodes 
(UOR = 2.55, 95% CI: 1.06 to 6.12, p=0.03). The small group of MSM with more than seven 
episodes of STI had a four times higher risk of having bacterial STIs detected (UOR=4.59, 
95% CI: 1.65 to 12.81, p<0.01).  
These results remained consistent when they were included in the multivariate model as shown 
in Table 4.9. There were significantly more STI cases in MSM who used condoms less 
frequently compared to those who consistently used a condom with an adjusted odds ratio 
(AOR)=2.39, 95% CI: 1.05 to 5.51, p=0.04). Table 4.9 also highlights that MSM who had one 
to three prior STI episodes were twice more likely to acquire bacterial STIs (AOR=1.92, 95% 
CI: 1.01 to 3.62, p=0.04).   
Univariate analyses indicated significant results for the variables of PrEP status and self-
reported number of sex partners. As shown in Table 4.9, the presence of bacterial STI was 
significantly higher among MSM who either used PrEP or had multiple partners. The risks of 
having STI were twofold among participants with PrEP (UOR=2.47, 95% CI: 1.44 to 4.23, 
p=0.001). Furthermore, MSM who had more than ten sexual partners within last three months 
appeared to have a bigger risk of STI (UOR=3.10, 95% CI: 1.26 to 7.62, p=0.01). However, 
both variables showed no significance in the multivariate model. This finding might be due to 
associations of PrEP status with multiple partnership and unsafe sex practice among 
participants in this study. Based on few analyses, MSM who use PrEP tend to practice 
condomless sex (OR=1.89, 95%CI: 1.56 to 2.31 p<0.001), had 6-10 partners (OR=1.85 95%CI: 
0.11 to 31.22 p>0.5), and had more than 11 partners (OR=6.0 95%CI: 0.32 to 112.25 p>0.2).  
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This study also indicated some risk factors which might have correlations with STI diagnoses. 
Table 4.9 shows that MSM aged <30 years old (UOR=1.13, 95% CI: 0.68 to 1.88, p<0.64), 
non-Australian born MSM (UOR=1.34, 95% CI: 0.80 to 2.22, p<0.26), and MSM without 
regular partners (UOR=1.36, 95% CI: 0.79 to 2.32, p<0.19) have a slightly greater risk of 
acquiring bacterial STIs. Meanwhile, bisexuals have nearly a 1.5 times higher chance of 
diagnosed with STIs compared to homosexual men (UOR=1.58, 95% CI: 0.79 to 3.13, p<0.19), 
and MSM who inject drugs are a twice higher risk of having STI diagnosis than those who are 
not (UOR=1.87, 95% CI: 0.52 to 6.81, p<0.34). These results show a number of important risk 
factors in STI transmission, although they did not present significant results in this analysis. 
4.4 Summary of result  
We found 26.7% of MSM had bacterial STIs despite not having any symptoms. Most often, 
these are ano-rectal infections of 9.8%. MSM who were diagnosed with STIs were currently 
on PrEP, having multiple partners, practicing unprotected sex, and having past STI diagnoses. 
However, the multivariable regression analysis only showed that STI diagnosis was 
significantly correlated with MSM who “sometimes” used condoms and those who had 1-3 
episodes of past STIs.   
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Chapter 5  
Discussion 
This study aims to measure the prevalence of bacterial STIs caused by three pathogens (CT, 
NG, MG) among asymptomatic MSM, as well as identifying the correlated factors of this key 
population in terms of having a bacterial STI diagnosis detected in the laboratory. Hypotheses 
tested in this study were that the prevalence of non-urethral infections among MSM outweighs 
urethral infections and that higher prevalence of each bacterial STI might be correlated with 
younger age, use of HIV PrEP, a history of STIs, having more sexual partners as well as using 
condoms less frequently with sex partners. This section will discuss the results in relation to 
other studies. The implications and weaknesses of this study, along with concluding 
recommendations, will be presented at the end of this Chapter  
5.1 Demographic characteristics 
There were 307 MSM attending the WSSHC Express clinic service during February-May 2017 
for routine STI screening and risk assessments. We found that the largest contribution of this 
study came from MSM aged under 40 years old (77.9%). The proportion of each age group in 
this study is relatively similar to that of a large survey among gay community in Australia since 
1996, the Gay Community Periodic Survey (GCPS) in Sydney, 2017 (250). In this study, MSM 
who aged 30-39 was the largest group (26.4% of total MSM population studied) and was 
similar to GCPS (30.2%). Approximately a quarter (25.4%) of those recruited to the current 
study were MSM aged <25 years old, which was a substantially higher proportion compared 
to GCPS (17.5%). Also, the number of older participants (>50 years old) was higher in this 
study than GCPS. The study population described in this thesis represented a subpopulation of 
MSM that presented for routine STI screening due to on-going sexual risk and thus was likely 
to be younger than the more diverse group of MSM residing in the local community.   
This study also recruited more immigrant (non-Australia born) MSM with a proportion of 
43.3%, higher than the Gay Community Periodic Survey with 37.6% of immigrant MSM 
population across Sydney in 2017 (250). The high number of non-Australia born MSM 
involved in the study might be influenced by the location of study setting, the WSSHC, 
Parramatta, where the proportion of overseas-born residents was relatively high (73.6%), 
according to the general population census in 2016 (251). Also, the New South Wales state 
itself experienced a high increase of foreign immigrants by 31% in 2017 (252). In the future, 
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this fact may lead to a mixed pattern of HIV-STI risks between migrant and local MSM while 
the pattern of the disease may be affected by diverse sexuality, sexual behaviours, and different 
bacterial strains from another country.  
5.2 Prevalence of bacterial STIs 
From a total of 921 samples taken from 307 asymptomatic MSM attending the WSSHC 
Express HIV/STI screening service, 82 MSM (26.7%) were found to be infected with at least 
one pathogen (CT, NG, MG) in one anatomical site (urethra, ano-rectum, oro-pharynx).  
Ano-rectal infection of CT was the most common STI among MSM participants, with a 
prevalence of 9.8%. This result was comparable to other studies (253-255) and higher than the 
ano-rectal CT prevalence of a study in Melbourne (5%) (145). A study in the US reported a 
higher prevalence with more than to 20% (256). In general settings, 60 to 95% of MSM with 
ano-rectal CT are asymptomatic (254, 257, 258). However, few patients may complain of non-
specific symptoms, such as anal pain, ulceration, ano-rectal discharge, and perianal bleeding 
(259). The prevalence of asymptomatic ano-rectal CT was higher than urethral and oro-
pharyngeal infections, similar to the result of some MSM studies (40, 253, 254).  
The risk of acquiring ano-rectal CT in MSM is associated with young age, inconsistent condom 
use, and sex under the influence of alcohol (260), and has a strong association with HIV-
positive status (167, 256, 260). HIV-infected MSM possessed three times higher risk of having 
ano-rectal CT (256). However, the multiple infections involving ano-rectal CT/NG and HIV 
does not necessarily increase HIV transmission to HIV-negative individuals. Several studies 
had shown no association of increased HIV shedding in the rectum due to ano-rectal CT / NG 
infections (261, 262). On the other hand, a significant increase of HIV RNA was found in 
semen and genital fluids of people with CT/NG urethritis and cervicitis (162, 164), carried 
through the accumulation of leucocytes concentration in the genital tract (162). Among HIV-
negative individuals, rectal CT/NG are associated with an increased risk of later HIV 
acquisitions (36, 263). A cohort study in Canada proved ano-rectal gonorrhoea as an 
independent risk factor for HIV seroconversion among homosexual men (36). Attachments of 
CT/NG in the rectal mucosa attracted T-lymphocyte migrations to the surface, led to increasing 
HIV-target cells (36). Also, two episodes of past ano-rectal CT/NG had an eight-fold higher 
risk of HIV acquisition among MSM (264).  
The ano-rectum was the anatomical site where the majority of co-infections of bacterial STIs 
were found. In this study, 15 individuals were determined to have two or more bacterial STIs, 
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and all but one of these co-infections were located in the ano-rectum. Many studies have 
correlated CT and NG as pathogens with a tendency to be sexually transmitted simultaneously 
(254, 265, 266). The prevalence of CT/NG co-infection at ano-rectal site was 1.6% in our study 
and somewhat lower than has reported in other studies where ano-rectal co-infections have 
been reported to occur at prevalence values exceeding 2% (254, 265). Infections of CT or NG 
affecting ano-rectal site were prevalent among MSM reported a high frequency of receptive 
anal intercourse with multiple partners (260).  
Interestingly, the prevalence of ano-rectal multi-pathogenic infection was detected more in 
CT/MG co-infections in this study with 2% in prevalence, while the co-infection of NG/MG 
was recorded only at 0.3% in the ano-rectum. It is tempting to suggest that there might be an 
as yet unknown biological mechanism responsible for enhancing co-transmission of CT and 
MG pathogens or, alternatively, a biological mechanism that makes it harder for MG infections 
to establish themselves in the presence of gonococcal infection, perhaps immunological in 
origin. At present, this is pure speculation and, given the relatively small numbers of co-
infection cases reported, however, further research is required to see if this observation persists 
in larger studies. Further research is also required to try and understand if these co-infections 
were acquired simultaneously or represent separate transmission events from different sexual 
partners. 
We found that the prevalence of MG infection in asymptomatic MSM was relatively high in 
our study. Indeed, the prevalence of ano-rectal and urethral MG was comparable to the 
prevalence of ano-rectal CT infection (9.4% vs 9.8%, respectively) and urethral CT infection 
(2.9% vs 2.3%). However, none of the 307 oro-pharyngeal swabs tested was positive for MG, 
which suggests that MG acquired through penile-anal intercourse. Few studies report on 
screening for MG in oro-pharyngeal site alone, and no published major study has yet calculated 
the prevalence of MG infection at this site. A cross-sectional study in which asymptomatic 
MSM was screened for MG showed no positive isolates in oro-pharynx (267).  
The evidence of MG identified in respiratory tracts was initially reported by Basemen et al., in 
1988, after the findings of mixed Mycoplasma pneumonia and Mycoplasma genitalium strains 
on throat swabs among soldiers receiving M. pneumonia vaccine (268). A newer study in China 
also found MG isolates in children with acute respiratory tract infection (269). However, the 
evidence that proves how MG spread through sex contacts remains limited. Microbiologically, 
MG uses MgPa surface protein to attach to the human mucous membrane, primarily to the 
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superficial layer of respiratory and urogenital tissue (270). MG can attach to erythrocytes, 
spermatozoa, and fallopian tube cells (271), yet positive oro-pharyngeal MG was extremely 
rare (267). Deguchi et al. performed MG investigation with the throat washing among female 
sex workers in Japan (272). The throat washing technique could increase the detections by 
scaling epithelial cells (272). However, this study failed to identify any single MG infection 
from the throat, instead showed positive results for other rare bacterial STIs, Mycoplasma 
hominis, Ureaplasma parvum, Ureaplasma urealyticum (272). The molecular attachment of 
MG to throat cells still needs to be explained more in the future.  
Overall, the prevalence of ano-rectal MG in this study was substantially higher than the study 
of asymptomatic MSM in Melbourne with 1.6% (267). Other studies among MSM (both 
symptomatic and asymptomatic) showed the prevalence of ano-rectal MG from 3 to 6% (37, 
128, 153). These various findings might be related to the use of different screening tools. This 
study was based on a screening method using a new diagnostic tool called the MG PlexPCR 
assay that detects the MG 23S rRNA gene as well as predicts expected susceptibility, or 
otherwise, to macrolide antibiotics. In most other studies, the procedures used a real-time PCR 
method that detects MG Pa gene (153, 267). Compared with the reference standard 
(conventional 16S rRNA gene PCR), both assays show a high sensitivity of 99.1% for MG 23S 
rRNA assay (132) and 97.4% for Mg Pa assay (273). Although both can be used as a trusted 
screening tool, these differences may provide a variation in the reported prevalence between 
studies. The observed high prevalence of asymptomatic MG infections may be seen as a public 
health concern and may warrant the introduction of screening of high-risk MSM for ano-rectal 
MG infection. However, we still lack evidence that ano-rectal MG causes proctitis and it might 
well be that the ano-rectum is a natural reservoir for MG bacteria. If this were the case, it might 
explain why MG infections only become troublesome after transmission to the male urethra, 
where the characteristic features of non-gonococcal urethritis may result in patients attending 
medical services for symptomatic relief. 
The high prevalence of MG delivers a warning for the increased HIV transmission in the MSM 
population. The strong association of HIV and MG infection established in some research 
involving women in sub-Saharan Africa (171, 274, 275) and among MSM in Australia (267) 
and China (128). Those studies showed the same result of higher MG prevalence among HIV-
positive than HIV-negative individuals. A longitudinal study by Mavedzenge et al. stated that 
MG was the only non-viral STI independently associated with high HIV transmission (275). 
One possible explanation describing the role of MG in promoting HIV transmission is related 
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to host immune responses. In vitro, the attachment of MG in endocervix has invited HIV-
susceptible inflammatory cells to the surface of genital mucosa which boosts the likelihood of 
human cells-virus bindings (276). Also, the host cell inflammatory response and cytokine 
secretion play a major role in tissue damages that impaired the mechanical barrier against 
microorganisms (276). Also, MG infections might persist for months, with or without treatment 
(277, 278), leading to longer duration of HIV spread within a population. Furthermore, 
implementing routine MG screening especially in HIV-positive MSM in the future might be 
useful to control HIV transmission (153) 
Despite being one of the important causes of NGU, the prevalence of urethral MG was 
relatively small in this study (2.9%). However, this finding was much higher than another study 
among asymptomatic MSM in Melbourne (0.6%) (267) but much lower than a study involving 
symptomatic MSM in Adelaide (8.1%) (150). Again, the different diagnostic tools used in these 
studies might cause the differences. Also, MG urethritis among men is frequently followed by 
dysuria and/or urethral discharge (124, 279). In this thesis study, there was one participant with 
urethral MG that reported no sex partner in the last three months. This finding suggests that 
persistent asymptomatic urethral MG may occur. Either persistent or recurrent infection of MG 
is common. A study in Uganda reported that a spontaneous remission was notified in 53% of 
women within three months, leaving the rests still persistent (274). Persistent symptoms of 
urethritis might be found 90-days post-therapy (278) and the reports of antibiotic-resistance 
MG also continue to develop against azithromycin (280) and moxifloxacin (28). Testing of 
cure and antimicrobial resistance tests become more important in the future to control MG 
infections.  
With respect to gonococcal infection, this study demonstrated that the most frequent anatomical 
site of infection with NG was the oro-pharynx (5.5%). This prevalence of oro-pharyngeal 
gonorrhoea was similar to prevalence data reported in other MSM studies (38, 207). In MSM 
population, the reported prevalence of oro-pharyngeal gonorrhoea ranges from 3-15% (38-40, 
207). The presence of oro-pharyngeal gonorrhoea among MSM has become a significant 
concern due to high intensity and variety of sex involving mouth as well as the propensity for 
antimicrobial resistance to emerge in this site due to the acquisition of resistance determinants 
by NG from commensal bacteria residing in the same anatomical site (7, 281). A recent 
mathematical model has suggested that kissing may play a major role in enabling high NG 
transmission rates within MSM networks (232). However, this retrospective study was not able 
to present details of sexual contacts experienced by each participant due to the absence of 
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interviews with clients. Classically, more than 90% of oro-pharyngeal gonorrhoea cases are 
asymptomatic and mostly detected on screening (38, 39, 207). Furthermore, one study 
demonstrated no correlation between oro-pharyngeal gonorrhoea and throat symptoms (207). 
Co-infections involving oro-pharyngeal gonorrhoea are infrequent given that CT and MG both 
prefer to infect ano-genital mucosal surface.  
The rising trend of global oro-pharyngeal NG is causing concerns in the future of gonococcal 
pharmaceutical therapy. Oro-pharyngeal gonorrhoea was strongly associated with treatment 
failure (282, 283). The first high-level resistance of NG was identified in Japan from throat 
isolates of sex workers (77). In other areas, the later cases of ceftriaxone failure were later 
reported from the oro-pharyngeal NG (284, 285). A systematic review of 144 trials compared 
the cure rate of three main sites of NG infection which showed low efficacy among male 
samples on oro-pharyngeal site (79% of cure), compared to ano-rectal (95%) and urethral 
(97%)(91). 
The important mechanism that causes ineffective antimicrobial actions on throat might be 
associated with the roles of commensal bacteria. The oro-pharynx is an ideal niche for a lot of 
bacteria, one of which is Neisseria. Non-pathogenic Neisseria are found in a small proportion 
within genital organs, but abundant on the throat (286). Neisseria living in the respiratory tract 
are frequently exposed to oral antibiotics allowing bacterial adaptations towards antimicrobial 
effects (281). Therefore, isolations of NG from oro-pharyngeal swabs might promote genetic 
interactions with commensal Neisseria. In the case of cephalosporin-resistance NG, a 
horizontal exchange of genetic materials from commensal Neisseria to NG has produced 
mosaic penA genes that are suspected to be the primary cause of resistance (84, 287). These 
resistant strains then might spread to other organs (rectum and urethral) due to penile oral or 
anal-oral sex contacts. Oro-pharyngeal NG, despite known as a self-limiting disease (288), is 
a primary reservoir of NG infection and a promoter of antimicrobial resistance. However, 
public health interventions often find limitations in promoting safe oral contacts among 
populations.  As condom use during oral sex is difficult to practice, the use of gargling with 
alcohol-containing mouthwash may be a solution, although it still requires further study, ideally 
in a randomized controlled manner; such a study is already on-going (230) 
Overall, we found that the prevalence of non-urethral bacterial STI was five times higher than 
urethral sites among asymptomatic MSM. This may be related to the high tendency for urethral 
infections to present with urethral discharge and/or dysuria whilst most ano-rectal and oro-
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pharyngeal infections are asymptomatic (39). Sexual contact between MSM often involves 
exposure to three mucosal surfaces at the urethra, ano-rectum, and oro-pharynx. Transmission 
frequencies vary between the mucosal surfaces and can account for transmissions (7, 232). 
Unfortunately, this study did not obtain information on the recent frequency of sex and sexual 
type performed by participants as patient-collected data relied on the CASI data entry by the 
patients attending the Express clinic. The prevalence of asymptomatic urethral gonorrhoea was 
low (0.3%, or 1 in 307 asymptomatic MSM) compared with the prevalence of asymptomatic 
ano-rectal NG (4.6%, or 1 in 22 asymptomatic MSM) and oro-pharyngeal NG (5.5%, or 1 in 
18 asymptomatic MSM). Urethral NG is one of the most important causes of urethritis among 
MSM and the majority of cases present with classical urethral symptoms of urethral discharge 
with marked dysuria.  A study in Melbourne demonstrated that over 90% of MSM with urethral 
NG cases showed the presence of urethral discharge and/or dysuria, four days after the last 
sexual contact (29). The screening of urinary samples among asymptomatic males in the UK 
also did not find any NG infection, compared with the 6% of positive CT in the same urine 
sample (266). However, in countries where the prevalence of gonorrhoea is very high and STI 
management based on syndromic management of symptomatic disease, for example, South 
Africa, community-based NAAT screening has highlighted the importance of asymptomatic 
urethral gonorrhoea in maintaining transmission among key populations. In a study of miners 
in an informal settlement, the prevalence of asymptomatic gonorrhoea was 4.7% (1 in 21 men) 
which is about 15-fold higher than the prevalence reported in this study. Community burden of 
asymptomatic STIs increases in the absence of regular screening (28).  
5.3 Factors associated with bacterial STI diagnosis 
Univariate or multivariate analyses showed the significance of some selected risk factors 
related to the diagnosis of bacterial STIs. The study indicated that the STI diagnosis had 
significant correlations with engaging in sexual intercourse with multiple partners, less 
frequent use of condoms, a larger number of previous STI episodes and use of PrEP for HIV 
prevention.  
5.3.1 Multiple partners and inconsistent condom use 
MSM tends to have multiple partners and concurrent sexual partnerships. In this study, more 
than 80% of participants had sex with two or more partners in the last three months. In the 
univariate analysis, MSM with more than ten partners within three months had a threefold 
higher risk of acquiring STIs compared to MSM with one partner. Other studies have indicated 
the similar findings (269, 289). Unique sexual behavioural characteristics of MSM were 
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described in a study measuring the age of sexual debut among MSM, which was determined to 
be at a younger age in MSM compared with heterosexual males (290). Young MSM are also 
likely to build relationships with older partners, which possibly increase their risks to HIV 
acquisition (291, 292). A gay man’s desire to look for a new partner will continue until the age 
of 30s (290). Cumulatively, MSM had twice longer periods of seeking new partner than 
heterosexual men during their life (290). A survey indicated that MSM consistently seek new 
partners as they wished to experience different feelings and to satisfy their high sexual desires 
(293). This survey also mentioned that MSM who actively recruit partners through online 
media tend to have multiple partners (293). 
Both univariate and multivariate analysis demonstrated a significant correlation between 
inconsistent condom use and positive STI diagnosis. The reasons underlying inconsistent 
condom use are multiple, and range from personal choice, pressure from sexual partners, 
having sex with partners taking PrEP and recreational drug use (254, 294, 295). Few studies 
also related the low frequency of condom use among MSM who had multiple and concurrent 
sex partners (293, 296). MSM involving in transactional sex also made safe sex practices less 
likely (254). Uniquely, the self-perception of high HIV risks did not improve the awareness of 
MSM in practising safe sex, either in developing countries such as Cote d'Ivoire (297) as or in 
developed countries like China (298). This might indicate that educational levels and social 
status of MSM may not have a major influence on sexual behaviour practices. Recent studies 
showed interesting findings at the role of internet dating in affecting safe sexual practice among 
MSM (299, 300). In online dating, users usually put their condom preference status which 
might increase the chance of a meeting of MSM who are reluctant to wear condoms (301). 
Both multiple partners and inconsistent condom use relate to the high frequency of internet use 
by gay men in search of a partner. With a rising trend of internet users in recent years, public 
health interventions should involve more online media for health promotions. 
5.3.2 PrEP for HIV prevention 
This study found an interesting result in which PrEP-user MSM significantly increased the risk 
of STI diagnosis in univariate analysis, but this evidence had lost significance in the 
multivariate model (Table 4.9). PrEP considered as one of STI risk factors in recent years did 
show contradictory results in several studies (294, 302, 303). A retrospective cohort study 
involving MSM in Vietnam reported that the risk of STI detection was doubled after 12 months 
of PrEP use (294). A systematic review conducted by Kojima et al. calculated the incidence 
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rate ratio among MSM with and without PrEP. Reviewing 18 cohort studies, the incidence rate 
of NG, CT, and syphilis was 23, 11, and 44 times higher among PrEP user MSM, respectively 
(200). However, this meta-analysis was not supported by an adequate technique of 
heterogeneity and an appropriate comparison of sexual behaviour profiles of each primary 
study (200).  
The high rate of STI diagnosis in gay men with PrEP might be associated with increased STI 
screening in PrEP users (304), multiple partners (199) and inconsistent condom use during sex 
intercourse (294). For this thesis study, the proportion of PrEP users who had more than ten 
partners was 17.5%, which was five times higher than no PrEP (3.5%). Also, the proportion of 
consistent condom use was much higher among MSM not on PrEP (55.6%) compared to PrEP 
users (15.7%). Statistical analyses show a significant correlation between PrEP use and 
inconsistent condom use where MSM who used PreP were nearly twice as likely to practice 
condomless sex (OR=1.89, 95%CI: 1.56 to 2.31 p<0.001). PreP uses may also correlate with 
multiple sexual partnerships, yet this was not statistically significant (OR=1.85 95%CI: 0.11 
to 31.22 p>0.5).  
In contrast, some studies found no correlations between STI diagnosis and the use of PrEP 
(302, 303, 305). A systematic review by Freeborn et al. found no significant associations 
between PrEP and the rate of STIs, as well as with low condom use in MSM (305). The PROUD 
trial in 2016 also indicated no evidence of a higher STI diagnosis during the PrEP intervention 
(302). The most recent systematic review of MSM showed contrasting results, where PrEP was 
significantly associated with an increased risk of ano-rectal chlamydia, but not significant for 
STI incidence in general (306). These inconsistent results will make the correlation study of 
PrEP, sexual behaviours, and STI diagnosis still relevant to the population. This can help to 
determine appropriate public health strategies in PrEP users. 
5.3.3 History of past STI episodes 
Both univariate and multivariate analysis in this study indicated a significant correlation of the 
number of previous STI episodes with the diagnosis of bacterial STI. The correlation between 
increased risks of STI acquisition and the past of STI was also seen in some studies (39, 295). 
In this WSSHC study, 62.2% of total participants had at least one episode of past STI. This 
figure indicates that gay men repeatedly engage in high-risk sexual behaviours. A study in STI 
clinics in the US involving both men and women, indicating past STI episodes associated with 
high-risk behaviours, such as low rate of condom use and multiple partners (307). In the MSM 
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study, high rates of past STI episodes had correlations with HIV-positive status (308). Specific 
to ano-rectal infection in MSM population, a history of two prior rectal infections (CT or NG) 
might increase the risk of HIV up to eight-fold (260). In this context, HIV-negative MSM 
having multiple episodes of past STI especially ano-rectal infections represent a population in 
need of extensive HIV prevention strategies, like PrEP.  
5.3.4 Other factors  
In this study, young age is one of those which were not significantly correlated with STI 
diagnosis. The evidence of higher STI prevalence in young MSM has been reported previously 
(208, 260). A further study described that young MSM had a higher tendency to explore their 
identity and sexuality, including sexual identity which leads to high-risk sexual behaviours 
(309). The growing uses of internet and social media by young MSM can facilitate the younger 
generation to recruit sex partners (208). In some studies, young age was associated with higher 
frequency of sex and unprotected anal intercourse among MSM (310, 311). Therefore, public 
health interventions to avoid high-risk sexual behaviour among all ages is more important than 
targeting specific MSM sub-group. However, Internet-based health promotion strategies might 
yield some benefit among young MSM as they frequently recruit online sexual partners.  
5.4 Limitation of this study 
5.4.1 Lack of sample coverage  
We limited our data inclusion to clients attending the nurse-led Express clinic in WSSHC based 
in Parramatta, New South Wales, Australia. This study is therefore only relevant to patients 
attending this particular clinical service.  The study failed to include other asymptomatic clients 
who came to the regular clinic in WSSHC to see doctors. This group consisted primarily of 
MSM living with HIV who were attending the service for routine HIV follow-up appointments 
and scripts but also asymptomatic patients unable to access the Express service due to 
unavailability of free appointment slots and symptomatic patients requiring an interpretor 
service as they would not be able to read and answer the questions on the CASI.  
5.4.2 Failure to include MSM living with HIV 
HIV status is an important risk factor to study in research projects addressing the acquisition 
bacterial STIs by MSM. However, as the majority of HIV-positive went to the regular clinic 
and not through the Express services, we were unable to perform a regression analysis of HIV 
and STI risks in the present study.  
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5.4.3 Retrospective data 
A retrospective study does not allow researchers to control for information obtained directly 
from participants. This study collected secondary data from primarily patients’ notes with 
electronic data as the compliment. Data was limited to MSM clients using the Express clinic 
machine voluntarily, where the device is already set up with certain questions. So, researchers 
did not have the opportunity to monitor and validate the truthfulness of the responses. Such a 
retrospective analysis cannot obtain details of important variables to enrich the analysis, such 
as the use of recreational drugs such as gamma hydroxybutyrate or methamphetamines (unless 
injected). 
5.4.4 Small sample size of MSM with bacterial STIs 
In the tables of univariate and multivariate analysis (Table 4.9), it can be seen that some 
variables presented pictures of wide confidence interval despite significance in statistical 
analyses. A wide margin of error produces less precise and less confidence information. The 
relatively small number of positive STIs in the asymptomatic MSM population was responsible 
for the large range of confidence intervals that were observed. 
5.5 Implications and recommendations 
Trends in the prevalence of bacterial STI among asymptomatic MSM are important to monitor 
as they provide important data on the burden of bacterial STI cases in this key population. In 
addition, a prevalence study including the assessment of sexual behaviour will provide benefits 
in monitoring the success of health promotion implemented in a given MSM population.  
The high prevalence of MG infection, especially ano-rectal MG, found in this study may basis 
for future studies. Although MG infection is increasingly recognized for its importance as a 
STI, screening for MG has not yet been included in the standard STI screening guideline for 
asymptomatic clients in Australia or elsewhere in the world. A more extensive study involving 
multiple geographical sites will show the real burden of MG infection among key populations, 
like MSM. We need transmission studies to provide the evidence to demonstrate that 
asymptomatic ano-rectal carriage is associated with both proctitis in index patients and 
symptomatic urethral infection in sex partners. Should this be the case, there would be more of 
a case to support the provision of MG screening among MSM. MG screening among MSM 
might be essential in the future due to asymptomatic deployment, further implicating on HIV, 
co-infection causes, and the probability of antimicrobial resistance.   
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The low prevalence of urethral NG among asymptomatic MSM as shown in this study supports 
the current STI screening programs for MSM in New South Wales. The STIGMA guidelines 
recommended that asymptomatic MSM are only screened for NG at the oro-pharyngeal and 
ano-rectal sites on the basis that almost all urethral NG infections are symptomatic. A larger 
prevalence study that can compare the proportion of symptomatic and asymptomatic urethral 
gonorrhoea may help to describe further define the extent to which asymptomatic urethral NG 
presents in clinical practice. Furthermore, a cost-effectiveness study related to the importance 
of urine screening for gonorrhoea in asymptomatic cases will help to evaluate the current STI 
guidelines. Delaying immediate urine screening for NG among asymptomatic men may give 
more benefits in the future. This recommendation is useful in low-resource settings where the 
provision of NG screening is limited.  
The study presented a brief overview of several key behavioural traits of MSM attending the 
Express clinic service, for example, the low rate of consistent condom use and the high number 
of MSM with multiple partners. These findings are helpful to direct future health promotion 
strategies. In addition to promotional content, goals should be tailored towards more high-risk 
communities.  
To increase the data validity on the prevalence of bacterial STI among asymptomatic MSM in 
Australia, a cross sectional study involving larger samples is required and which would ideally 
involve a more diverse population, i.e. community members as well as clinic attendees, in order 
to a more precise conclusion and provide an opportunity to study the prevalence of 
asymptomatic bacterial STIs in various MSM sub-groups. A larger prospective study could 
also help by generating more detailed and accurate information from participants as to 
demographic, behavioural and clinical risk factors. 
5.6 Conclusion 
This thesis study indicated that the prevalence of bacterial STI in asymptomatic HIV-negative 
MSM was high. A quarter of the total participants were diagnosed with at least one of three 
bacterial STIs at any anatomical site. Non-urethral infections were still by far more prevalent 
than urethral infection, specifically the ano-rectal site. Ano-rectal CT, ano-rectal MG, and oro-
pharyngeal NG were three most common diagnoses in this asymptomatic MSM study. 
Interestingly, the new STI pathogen, Mycoplasma genitalium, had a relatively high prevalence 
in asymptomatic MSM. Co-infections within asymptomatic MSM population were found in a 
small proportion, with most involving CT and located in the ano-rectum. 
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MSM who were on PrEP or having multiple partners had significant associations with STI 
diagnosis. These associations were stronger among MSM having past episodes of STI and 
practising more condomless sex. This study could be the basis for the development of other 
studies with improved methodology and larger samples. These results might also be helpful in 
determining the STI screening program in the future. 
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